Josephine McCarthy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Josephine McCarthy has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jun Yang
Department of Medicine, Monash University, Clayton, Victoria, Australia (J.Y.).
2 shared publications Ben Clissold
Neurology (B.C., T.P.), Monash Health, Clayton, Australia
1 shared publicationFrank M. Gao
Department of Endocrinology (J.M.C., F.M.G., I.J.H.L., J.H.N.C.L., S.G.), Eastern Health, Box Hill, Victoria, Australia
1 shared publication- Ignatius J.H. Lee
Department of Endocrinology (J.M.C., F.M.G., I.J.H.L., J.H.N.C.L., S.G.), Eastern Health, Box Hill, Victoria, Australia
1 shared publication - Jane E Love
Department of Obstetric Medicine and Nephrology Eastern Health Melbourne Victoria Australia
1 shared publication - Jocelyn Widjaja
Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia (J.M.C., J.W., T.G.P., J.Y.).
1 shared publication
Latest Publications
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 493-498
Testing for Primary Aldosteronism Underutilized Following Stroke: A Multicenter Cohort Study
BACKGROUND: Primary aldosteronism, the most common endocrine cause of hypertension, is associated with an increased risk of stroke compared with essential hypertension. Targeted treatment with mineralocorticoid receptor antagonists, or surgical resection of an aldosterone-producing adrenal adenoma, can effectively reduce blood pressure and mitigate cardiovascular risk. However, despite being a highly modifiable cardiovascular risk factor, primary aldosteronism is grossly underdiagnosed, even in high-risk populations. METHODS: We conducted a multicenter retrospective cohort study to assess the frequency of primary aldosteronism testing among patients admitted between January 2019 to January 2020 with stroke or transient ischemic attack. Data, including blood pressure, antihypertensive medication use, serum potassium, and adrenal imaging, were collected from the medical records of patients admitted for stroke or transient ischemic attack at 2 large tertiary hospitals in Victoria, Australia. RESULTS: Among 400 patients (mean age, 73.9±13.4 years; 42.1% female), 30% (n=120) had a clinical indication for primary aldosteronism testing, yet only 2% (n=8) were tested. CONCLUSIONS: These findings highlight a missed opportunity to identify a treatable cause of hypertension in patients at high risk of recurrent cerebrovascular events. Routine testing for primary aldosteronism in stroke care pathways may improve long-term outcomes through targeted intervention.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 493-498
Testing for Primary Aldosteronism Underutilized Following Stroke: A Multicenter Cohort Study
BACKGROUND: Primary aldosteronism, the most common endocrine cause of hypertension, is associated with an increased risk of stroke compared with essential hypertension. Targeted treatment with mineralocorticoid receptor antagonists, or surgical resection of an aldosterone-producing adrenal adenoma, can effectively reduce blood pressure and mitigate cardiovascular risk. However, despite being a highly modifiable cardiovascular risk factor, primary aldosteronism is grossly underdiagnosed, even in high-risk populations. METHODS: We conducted a multicenter retrospective cohort study to assess the frequency of primary aldosteronism testing among patients admitted between January 2019 to January 2020 with stroke or transient ischemic attack. Data, including blood pressure, antihypertensive medication use, serum potassium, and adrenal imaging, were collected from the medical records of patients admitted for stroke or transient ischemic attack at 2 large tertiary hospitals in Victoria, Australia. RESULTS: Among 400 patients (mean age, 73.9±13.4 years; 42.1% female), 30% (n=120) had a clinical indication for primary aldosteronism testing, yet only 2% (n=8) were tested. CONCLUSIONS: These findings highlight a missed opportunity to identify a treatable cause of hypertension in patients at high risk of recurrent cerebrovascular events. Routine testing for primary aldosteronism in stroke care pathways may improve long-term outcomes through targeted intervention.
- 25 April 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (4) , 651-653
Wernicke encephalopathy in pregnancy
- 25 April 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (4) , 651-653
Wernicke encephalopathy in pregnancy
- 1 October 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (10) , E626-E634
Hypertension Management in Stroke Prevention
Primary aldosteronism confers a higher risk of stroke, atrial fibrillation, and cardiovascular disease than blood pressure matched essential hypertension. It is the most common endocrine cause of secondary hypertension with prevalence estimates of up to 13% in primary care and 30% in referral centers around the world. Unlike essential hypertension, primary aldosteronism has targeted medical treatment and potentially curative surgical solutions which can ameliorate the associated cardiovascular risks. This narrative review highlights an evidence gap in the optimal diagnosis and targeted treatment of primary aldosteronism in secondary stroke prevention. Over half of the patients suffering a stroke have blood pressure in the hypertensive range and less than a third achieve optimal blood pressure control. There are no guideline recommendations to test for primary aldosteronism in these patients, although up to 30% of patients with resistant hypertension may have this disease. The accurate diagnosis of primary aldosteronism could significantly improve blood pressure, simplify the medication regimen and reduce the overall cardiovascular risk in these patients. The challenges associated with screening for primary aldosteronism following stroke may be overcome by novel blood tests which are less affected by antihypertensive medications routinely used in stroke care. Approximately one-quarter of all strokes occur in patients who have previously had a stroke. Modifying hypertension, the leading modifiable risk factor, would, therefore, have significant public health implications. As clinicians, we must increase our awareness of primary aldosteronism in patients with stroke, particularly in those with resistant hypertension, to enable targeted therapy and reduce the risk of stroke recurrence.
- 1 October 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (10) , E626-E634
Hypertension Management in Stroke Prevention
Primary aldosteronism confers a higher risk of stroke, atrial fibrillation, and cardiovascular disease than blood pressure matched essential hypertension. It is the most common endocrine cause of secondary hypertension with prevalence estimates of up to 13% in primary care and 30% in referral centers around the world. Unlike essential hypertension, primary aldosteronism has targeted medical treatment and potentially curative surgical solutions which can ameliorate the associated cardiovascular risks. This narrative review highlights an evidence gap in the optimal diagnosis and targeted treatment of primary aldosteronism in secondary stroke prevention. Over half of the patients suffering a stroke have blood pressure in the hypertensive range and less than a third achieve optimal blood pressure control. There are no guideline recommendations to test for primary aldosteronism in these patients, although up to 30% of patients with resistant hypertension may have this disease. The accurate diagnosis of primary aldosteronism could significantly improve blood pressure, simplify the medication regimen and reduce the overall cardiovascular risk in these patients. The challenges associated with screening for primary aldosteronism following stroke may be overcome by novel blood tests which are less affected by antihypertensive medications routinely used in stroke care. Approximately one-quarter of all strokes occur in patients who have previously had a stroke. Modifying hypertension, the leading modifiable risk factor, would, therefore, have significant public health implications. As clinicians, we must increase our awareness of primary aldosteronism in patients with stroke, particularly in those with resistant hypertension, to enable targeted therapy and reduce the risk of stroke recurrence.